Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer

Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases

(2018) Heini M. L. Kallio et al.   BRITISH JOURNAL OF CANCER

Cancer statistics, 2018

(2018) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Chemopreventive effects of angiotensin II receptor type 2 agonist on prostate carcinogenesis by the down-regulation of the androgen receptor

(2018) Yusuke Ito et al.   Oncotarget

GPX2 promotes development of bladder cancer with squamous cell differentiation through the control of apoptosis

(2018) Taku Naiki et al.   Oncotarget

miRNA-mediated TUSC3 deficiency enhances UPR and ERAD to promote metastatic potential of NSCLC

(2018) Young-Jun Jeon et al.   Nature Communications

Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide

(2017) Emmanuel S. Antonarakis et al.   JOURNAL OF CLINICAL ONCOLOGY

Androgen Mediated Regulation of Endoplasmic Reticulum-Associated Degradation and its Effects on Prostate Cancer

(2017) Yalcin Erzurumlu et al.   Scientific Reports

Identification of miR-30b-3p and miR-30d-5p as direct regulators of androgen receptor signaling in prostate cancer by complementary functional microRNA library screening

(2016) Binod Kumar et al.   Oncotarget

Cabozantinib Inhibits Abiraterone's Upregulation of IGFIR Phosphorylation and Enhances Its Anti-Prostate Cancer Activity

(2015) X. Wang et al.   CLINICAL CANCER RESEARCH

Dysregulation of miR-212 Promotes Castration Resistance through hnRNPH1-Mediated Regulation of AR and AR-V7: Implications for Racial Disparity of Prostate Cancer

(2015) Y. Yang et al.   CLINICAL CANCER RESEARCH

MicroRNAs in apoptosis, autophagy and necroptosis

(2015) Zhenyi Su et al.   Oncotarget

GPX2 overexpression is involved in cell proliferation and prognosis of castration-resistant prostate cancer

(2014) Taku Naiki et al.   CARCINOGENESIS

Galeterone Prevents Androgen Receptor Binding to Chromatin and Enhances Degradation of Mutant Androgen Receptor

(2014) Z. Yu et al.   CLINICAL CANCER RESEARCH

Luteolin inhibits matrix metalloproteinase 9 and 2 in azoxymethane-induced colon carcinogenesis

(2014) AK Pandurangan et al.   HUMAN & EXPERIMENTAL TOXICOLOGY

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

(2014) Emmanuel S. Antonarakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ellagic acid, a component of pomegranate fruit juice, suppresses androgen-dependent prostate carcinogenesis via induction of apoptosis

(2014) Aya Naiki-Ito et al.   PROSTATE

Luteolin supplementation adjacent to aspirin treatment reduced dimethylhydrazine-induced experimental colon carcinogenesis in rats

(2014) Neamt H. A. Osman et al.   TUMOR BIOLOGY

The p53/miR-34 axis in development and disease

(2014) M. Rokavec et al.   Journal of Molecular Cell Biology

The Role of Dietary Fat throughout the Prostate Cancer Trajectory

(2014) Katie Di Sebastiano et al.   Nutrients

Apocynin, an NADPH oxidase inhibitor, suppresses rat prostate carcinogenesis

(2013) Shugo Suzuki et al.   CANCER SCIENCE

Inflammation and prostate carcinogenesis

(2013) Yasutomo Nakai et al.   INTERNATIONAL JOURNAL OF UROLOGY

An androgen receptor N-terminal domain antagonist for treating prostate cancer

(2013) Jae-Kyung Myung et al.   JOURNAL OF CLINICAL INVESTIGATION

Expression of glutathione peroxidase 2 is associated with not only early hepatocarcinogenesis but also late stage metastasis

(2013) Shugo Suzuki et al.   TOXICOLOGY

Luteolin decreases IGF-II production and downregulates insulin-like growth factor-I receptor signaling in HT-29 human colon cancer cells

(2012) Do Young Lim et al.   BMC GASTROENTEROLOGY

Purple corn color inhibition of prostate carcinogenesis by targeting cell growth pathways

(2012) Ne Long et al.   CANCER SCIENCE

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

(2012) Howard I. Scher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Systematic Analysis of MicroRNAs Targeting the Androgen Receptor in Prostate Cancer Cells

(2011) P. Ostling et al.   CANCER RESEARCH

Upregulation of prostate-derived Ets factor by luteolin causes inhibition of cell proliferation and cell invasion in prostate carcinoma cells

(2011) Ke-Hung Tsui et al.   INTERNATIONAL JOURNAL OF CANCER

Abiraterone and Increased Survival in Metastatic Prostate Cancer

(2011) Johann S. de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

Organ specific Gst-pi expression of the metastatic androgen independent prostate cancer cells in nude mice

(2011) Taku Naiki et al.   PROSTATE

The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study

(2010) L R Molife et al.   BRITISH JOURNAL OF CANCER

Distribution and Biological Activities of the Flavonoid Luteolin

(2009) Miguel Lopez-Lazaro   MINI-REVIEWS IN MEDICINAL CHEMISTRY

Luteolin inhibits invasion of prostate cancer PC3 cells through E-cadherin

(2009) Q. Zhou et al.   MOLECULAR CANCER THERAPEUTICS

Suppression of prostate cancer in a transgenic rat model via γ-tocopherol activation of caspase signaling

(2009) Satoru Takahashi et al.   PROSTATE

microRNAs - powerful repression comes from small RNAs

(2009) Cong Ma et al.   Science in China. Series C, Life sciences / Chinese Academy of Sciences

Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer

(2008) R. Hu et al.   CANCER RESEARCH

Glutathione S-transferase Pi mediates proliferation of androgen-independent prostate cancer cells

(2008) N. Hokaiwado et al.   CARCINOGENESIS